MedTrace Logo

Evaluating the Safety and Feasibility of TLD for the Treatment of Severe Asthma

NCT02872298 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 2

Last updated 2022-04-12

No results posted yet for this study

Summary

Prospective, multicenter, single-arm (non-randomized) study of Targeted Lung Denervation (TLD) Therapy in subjects with severe asthma.

Conditions

Interventions

DEVICE

Targeted Lung Denervation (TLD)

The Nuvaira Lung Denervation System, manufactured by Nuvaira, Inc., is intended to deliver TLD Therapy using predetermined radiofrequency (RF) energy over a predetermined period of time to ablate airway nerve trunks which are located on the outside of the main bronchi.

Sponsors & Collaborators

  • Nuvaira, Inc.

    lead INDUSTRY

Principal Investigators

  • Nick ten Hacken, MD · University Medical Center Groningen (UMCG)

  • Pallav Shah, MD · Royal Brompton & Harefield NHS Foundation Trust

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
21 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-12-22
Primary Completion
2020-04-06
Completion
2020-04-06

Countries

  • France
  • Germany
  • Netherlands
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02872298 on ClinicalTrials.gov